Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEAP-015 first-line pembrolizumab + lenvatinib + chemotherapy in advanced/metastatic gastroesophageal adenocarcinoma
CTR20210371Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Aug 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of pembrolizumab, lenvatinib in gastroesophageal junction adenocarcinoma, gastric adenocarcinoma, esophageal adenocarcinoma (EAC), sponsored by Merck & Co.. Started Aug 2021; status: completed.
02
Drugs
pembrolizumablenvatinib
03
Conditions
gastroesophageal junction adenocarcinomagastric adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on CTR20210371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210371.